San Francisco, California–(Newsfile Corp. – December 25, 2024) – On December 9, 2024, just months after conducting an initial public offering in September 2024, BioAge Labs, Inc. ((NASDAQ:BIOA) It made the startling announcement that it was halting a phase 2 study of its lead product, Azelaprague, which aims to treat metabolic diseases such as obesity.
Hagens Berman has opened an investigation and is urging BioAge investors who bought shares in the company's initial public offering or on the open market and suffered significant losses to file their losses now.
Visit: www.hbsslaw.com/investor-fraud/bioa
Contact the company now: BIOA@hbsslaw.com
844-916-0895
Investigation by BioAge Labs, Inc. (BIOA):
The investigation focuses on the adequacy of BioAge's disclosures about safety data and other issues related to azelaprague, which the company said in IPO documents was “well-tolerated in 265 individuals across eight phase 1 clinical trials.”
BioAge's disclosures came into question after the market closed on December 6, 2024, when the company announced the discontinuation of the phase 2 STRIDES clinical trial evaluating azelaprague in combination with terizpatide for the treatment of obesity. BioAge said hepatitis has been observed in patients receiving azelaprague.
This news caused BioAge's stock price to fall approximately 80% on December 9, 2024.
“We are focused on whether BioAge was transparent to investors about the safety profile of azelaprag before the December 6 announcement,” said Reed Katherine, the Hagens Berman partner leading the investigation.
If you invested in BioAge and suffered significant losses, or have knowledge that may assist in the company's investigations, file your losses now »
If you would like more information and answers to frequently asked questions about the BioAge investigation, read more »
Whistleblowers: Persons with non-public information relating to BioAge should consider their options to assist in the investigation or take advantage of the SEC's whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, contact Catherine Reed at 844-916-0895 Or email BIOA@hbsslaw.com.
# # #
About Hagens Berman
Hagens Berman is a global, complex plaintiffs' rights litigation firm focused on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases that achieve real results for those harmed by corporate negligence and other wrongdoing. The Hagens Berman team has earned more than $2.9 billion in this area of law. More about the company and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235182
